Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34m) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The funding will enable the company to build its clinical pipeline and grow its proprietary unique antibody dataset to more than a billion sequences.

Similar stories